Submission is based on extrapolation analysis and results examining the effects of Rexulti ® (brexpiprazole) 2 to 4 mg/day in treating symptoms of schizophrenia in adolescent patients (13-17 years old ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results